HomeNewsScreenerChartsMapsGroupsPortfolioInsiderFuturesForexCryptoCalendarPricing
Theme 		Help

New Elite Feature: Chart Templates — Your indicators and design everywhere on Finviz

Learn More
Market News Market Pulse Stocks News ETF News Crypto News

OKYO Pharma LTD

Contributing Author

Recent Articles by OKYO Pharma LTD

Mar-19
OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO GlobeNewswire
Mar-19
OKYO Pharma Announces Director Acquires Shares OKYO GlobeNewswire
Mar-19
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares OKYO GlobeNewswire
Mar-18
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain OKYO GlobeNewswire
Feb-23
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress OKYO GlobeNewswire
Feb-12
OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares OKYO -19.35% GlobeNewswire
Feb-12
OKYO Pharma Announces Public Offering of Ordinary Shares OKYO -19.35% OKYO +11.28% GlobeNewswire
Feb-11
OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners OKYO -6.70% GlobeNewswire
Feb-10
OKYO Pharma Strengthens World Class Leadership Team with Appointment of Flavio Mantelli, MD, PhD as Chief Medical Officer OKYO +5.03% GlobeNewswire
Jan-30
OKYO Pharma Announces Acceptance of Urcosimod Phase 2 Study Results for Presentation at Prestigious ASCRS Annual Meeting OKYO GlobeNewswire
Jan-28
OKYO Pharma Announces Successful Type C Meeting with the FDA OKYO GlobeNewswire
Jan-23
FDA Approves Compassionate Use of Urcosimod (0.05%) for the Treatment of Neuropathic Corneal Pain OKYO -6.33% GlobeNewswire
Jan-05
OKYO Pharma Appoints Industry Veteran Robert J. Dempsey as Chief Executive Officer OKYO +7.62% GlobeNewswire
Dec-19
OKYO Pharma to Ring the Opening Bell at Nasdaq OKYO +8.56% GlobeNewswire
Dec-15
OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO -8.25% GlobeNewswire
Dec-11
OKYO Pharma Announces New Data Showing Favorable Corneal Nerve Outcomes in Phase 2 Study for Neuropathic Corneal Pain OKYO +6.93% GlobeNewswire
Dec-03
OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO -5.77% GlobeNewswire
Nov-21
OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO +10.99% GlobeNewswire
Nov-18
OKYO Pharma to Present at OIS XV in San Diego OKYO GlobeNewswire
Oct-29
OKYO Pharma to Present at BIO-Europe 2025 in Vienna OKYO +6.67% GlobeNewswire
Oct-16
OKYO Pharma Announces Chairman and Founder Acquires Shares OKYO GlobeNewswire
Sep-22
OKYO Pharma Announces Registration Pathway with 100 Patient Multi-Center Clinical Trial of Urcosimod in Neuropathic Corneal Pain OKYO +13.64% GlobeNewswire
Jul-17
OKYO Pharma Receives $1.9 Million in Non-Dilutive Funding to Accelerate Development of Urcosimod for Neuropathic Corneal Pain OKYO GlobeNewswire
Jul-16
OKYO Pharma Unveils Strong Phase 2 Clinical Trial Results for Urcosimod to Treat Neuropathic Corneal Pain OKYO +7.64% GlobeNewswire
Jun-11
OKYO Pharma to Present at the Bio International Convention OKYO +12.56% GlobeNewswire
May-19
OKYO Pharma to Present at the GPCRs-Targeted Drug Discovery Summit OKYO +7.91% GlobeNewswire
Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)